Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ChemoMetec Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Martin Behrens

İcra Kurulu Başkanı

DKK 2.9m

Toplam tazminat

CEO maaş yüzdesi	30.0%
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.5yrs

Son yönetim güncellemeleri

Recent updates

We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings

Sep 18

What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling You

Jul 29

Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%

Jul 29

Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 08

Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares

Dec 21

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Nov 15

ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 17

A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)

Sep 15

At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?

Jun 20

With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case

Jun 01

Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors

Jan 24

If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity

Oct 26

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Oct 05

Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?

Jul 18

Here's Why I Think ChemoMetec (CPH:CHEMM) Is An Interesting Stock

Mar 27

Do ChemoMetec's (CPH:CHEMM) Earnings Warrant Your Attention?

Dec 12

Here's Why I Think ChemoMetec (CPH:CHEMM) Might Deserve Your Attention Today

Aug 29

Here's Why I Think ChemoMetec (CPH:CHEMM) Might Deserve Your Attention Today

Apr 28

ChemoMetec A/S' (CPH:CHEMM) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 18

ChemoMetec (CPH:CHEMM) Is Growing Earnings But Are They A Good Guide?

Feb 10

What Type Of Shareholders Make Up ChemoMetec A/S' (CPH:CHEMM) Share Registry?

Jan 15

Do ChemoMetec's (CPH:CHEMM) Earnings Warrant Your Attention?

Dec 20

CEO Tazminat Analizi

Martin Behrens'un ücretlendirmesi ChemoMetec'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	DKK 3m	DKK 877k	DKK 136m

Tazminat ve Piyasa: Martin 'nin toplam tazminatı ($USD 433.75K ), Danish pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 1.76M ).

Tazminat ve Kazançlar: Martin şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Martin Behrens (32 yo)

less than a year

Görev süresi

DKK 2,923,041

Tazminat

Mr. Martin Helbo Behrens serves as CEO at ChemoMetec A/S since March 13, 2024. He is Chief Operating Officer of ChemoMetec A/S from December 2023. He was Vice Chief Operating Officer of ChemoMetec A/S from...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Martin Behrens	CEO & COO	less than a year	DKK 2.92m	Veri yok
Hans Glensbjerg	Deputy Chairman & Senior Advisor	no data	DKK 150.00k	0.27% DKK 20.8m
Kim Nicolajsen	Chief Financial Officer	less than a year	Veri yok	Veri yok
Christopher Runchel	Chief Sales Officer	no data	Veri yok	Veri yok
Marta Planaguma	Chief Marketing & Strategy Officer	less than a year	Veri yok	Veri yok
Lisbet Helles	Head of Marketing	less than a year	Veri yok	Veri yok
Søren Kjærulff	Head of R&D	no data	Veri yok	Veri yok
Bo Nielsen	Chief R&D Officer and Physicist & Project Manager	less than a year	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

44yo

Ortalama Yaş

Deneyimli Yönetim: CHEMM 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Hans Glensbjerg	Deputy Chairman & Senior Advisor	no data	DKK 150.00k	0.27% DKK 20.8m
Peter Reich	Independent Director	10yrs	DKK 100.00k	0.0083% DKK 637.8k
Kristine Faerch	Independent Director	4yrs	DKK 100.00k	0.00032% DKK 24.5k
Niels Thestrup	Chairman	3yrs	DKK 360.00k	0.011% DKK 857.6k
Betina Hagerup	Independent Director	3yrs	DKK 100.00k	0.0017% DKK 128.6k

3.5yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CHEMM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).

ChemoMetec Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

ChemoMetec A/S Announces CFO Changes

Independent Director recently bought kr.450k worth of stock

ChemoMetec A/S Announces CEO Changes

ChemoMetec A/S Announces Executive Changes

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Less than half of directors are independent

Recent updates

ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025

ChemoMetec A/S Approves Dividend

Upcoming dividend of kr.4.00 per share

ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA.

We Think That There Are More Issues For ChemoMetec (CPH:CHEMM) Than Just Sluggish Earnings

Dividend of kr.4.00 announced

Price target increased by 8.0% to kr.473

Full year 2024 earnings: EPS exceeds analyst expectations

ChemoMetec A/S provides earnings guidance for the year 2024/25

Investor sentiment improves as stock rises 17%

ChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025

What ChemoMetec A/S' (CPH:CHEMM) 27% Share Price Gain Is Not Telling You

Earnings Not Telling The Story For ChemoMetec A/S (CPH:CHEMM) After Shares Rise 27%

Investor sentiment improves as stock rises 15%

What Is ChemoMetec A/S's (CPH:CHEMM) Share Price Doing?

ChemoMetec A/S Announces CFO Changes

Independent Director recently bought kr.450k worth of stock

Investor sentiment improves as stock rises 17%

Now 20% overvalued

Price target increased by 14% to kr.513

Now 21% overvalued

Some Confidence Is Lacking In ChemoMetec A/S (CPH:CHEMM) As Shares Slide 32%

ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24

Investor sentiment deteriorates as stock falls 18%

Investor sentiment deteriorates as stock falls 16%

ChemoMetec A/S Announces CEO Changes

What ChemoMetec A/S' (CPH:CHEMM) 30% Share Price Gain Is Not Telling You

What Does ChemoMetec A/S's (CPH:CHEMM) Share Price Indicate?

Investor sentiment improves as stock rises 30%

Earnings Beat: ChemoMetec A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

First half 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

ChemoMetec A/S Maintains Earnings Guidance for the Year 2024

Price target decreased by 18% to kr.448

ChemoMetec A/S Announces Executive Changes

Unpleasant Surprises Could Be In Store For ChemoMetec A/S' (CPH:CHEMM) Shares

Investor sentiment improves as stock rises 30%

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Investor sentiment improves as stock rises 17%

Upcoming dividend of kr.6.00 per share at 1.8% yield

ChemoMetec A/S (CPH:CHEMM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

A Look At The Intrinsic Value Of ChemoMetec A/S (CPH:CHEMM)

Chemometec A/S Proposes Dividend for the 2022/23 Financial Year

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Financial data availability

ChemoMetec A/S to Report Fiscal Year 2024 Results on Sep 11, 2024

At kr.467, Is ChemoMetec A/S (CPH:CHEMM) Worth Looking At Closely?

With EPS Growth And More, ChemoMetec (CPH:CHEMM) Makes An Interesting Case

ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023

First half 2023 earnings released: EPS: kr.6.06 (vs kr.4.90 in 1H 2022)

Investor sentiment deteriorates as stock falls 20%

ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023

Here's Why ChemoMetec (CPH:CHEMM) Has Caught The Eye Of Investors

Investor sentiment deteriorated over the past week

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Less than half of directors are independent

ChemoMetec A/S Provides Earnings Guidance for the Financial Year 2022-23

If EPS Growth Is Important To You, ChemoMetec (CPH:CHEMM) Presents An Opportunity

Is It Time To Consider Buying ChemoMetec A/S (CPH:CHEMM)?

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: kr.9.16 (vs kr.5.08 in FY 2021)

ChemoMetec A/S Provides Revenue Guidance for the Fiscal Year 2023

Does ChemoMetec (CPH:CHEMM) Deserve A Spot On Your Watchlist?

ChemoMetec A/S, Annual General Meeting, Oct 12, 2023

Less than half of directors are independent

Here's Why I Think ChemoMetec (CPH:CHEMM) Is An Interesting Stock

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Do ChemoMetec's (CPH:CHEMM) Earnings Warrant Your Attention?

Upcoming dividend of kr.4.00 per share